
|Articles|July 28, 2015
Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Real-World Data Favor GLP-1 vs Aspirin in Colorectal Cancer Prevention
2
Why Is Real-World Evidence Important to Your Practice?
3
Transportation, Logistics of Importance to Community Care With CDK4/6 Inhibitors
4
Zanidatamab/Chemo ± Tislelizumab Shows Frontline SOC Promise in GEA
5






























































































